Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants
Buprenorphine Effectiveness Evaluation in HIV Enhancement (BEEHIVE): A Randomized Trial of HIV Clinic-based Buprenorphine/Naloxone vs. Case Management and Referral in Opioid-dependent Individuals
The purpose of this study is to compare the effectiveness of two approaches to treating HIV-infected patients who are addicted to opioid drugs (e.g., heroin) in an inner-city HIV clinic. The two approaches are:
- Case management and referral - participants are managed by a case manager and referred to a specialized drug treatment center where they receive counseling and medications for opioid-dependence (e.g., methadone or buprenorphine); or
- Clinic-based treatment - participants receive counseling and treatment with buprenorphine at the HIV clinic.
調査の概要
状態
詳細な説明
We, the investigators at Johns Hopkins University, propose to enroll and randomize 120 opioid-dependent, HIV-infected participants, who receive care in the Johns Hopkins HIV Clinic to either:
- clinic-based care with buprenorphine (clinic-based BPN/NX arm); or
- case management and referral to an opioid treatment program for opioid agonist-based therapy (case management and referral arm).
The study interventions and follow-up will last 12 months. Participants will be enrolled over a 3-year period. Participants who are assigned to the clinic-based BPN/NX arm will receive BPN/NX (Suboxone®), individual counseling from a nurse interventionist, and group therapy sessions. Participants who are assigned to the case management and referral arm will be enrolled in an established case management and adherence program in the Johns Hopkins HIV Clinic (Project LINK). LINK provides intensive case management, education, and support by a team that includes a social worker, a nurse, a pharmacist educator, and peer advocates. In addition to providing counseling and linkage to needed services, LINK will expedite intake at licensed opioid treatment programs that provide agonist-based therapy for opioid dependence. The clinic-based BPN intervention is a new strategy that was developed in a pilot project over the past 6 months. The case-management and referral arm represents standard-of-care in our clinic, which has been enhanced and codified for this trial. Study outcome visits will be performed at baseline, 1 month, 3 months, 6 months, 9 months, and 12 months.
Comparisons:
- Retention to substance abuse treatment;
- Urine drug screens;
- Adherence to HIV primary care provider visits;
- Use of and adherence to highly active antiretroviral therapy (HAART);
- HIV RNA levels and CD4 cell counts;
- HIV transmission risk behaviors (e.g., injection, sharing of drug paraphernalia, sexual behaviors);
- Costs and resource utilization.
研究の種類
入学 (予想される)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- Johns Hopkins HIV Clinic
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- HIV-infected and receiving continuity care in the Johns Hopkins HIV Clinic
- 18 years of age or older
- Meets DSM-IV criteria for opioid dependence
- Seeks agonist-based treatment for opioid dependence
- Willing and able to provide written informed consent
- Willing to be contacted by mail and telephone for study follow-up visit reminders
- Willing to authorize release of information for substance abuse treatment to the study for a period of 12 months
- If female, negative urine pregnancy test and willingness to practice birth control while on study if sexually active (barrier method or progesterone-containing contraception product)
- Verbal approval from participant's primary HIV clinician
Exclusion Criteria:
- Currently receiving methadone, naloxone, buprenorphine, or levomethadyl acetate (LAAM) as part of a licensed opioid treatment program
- History of allergic reaction to buprenorphine or naloxone
- Active medical need for opioid-based pain control
- Active benzodiazepine abuse or dependence
- Active alcohol dependence
- Alanine aminotransferase level that is more than 5 times the upper limit of normal
- Other condition that, in the opinion of the principal investigator, makes participation in the study unsafe or follow-up highly unlikely
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:1
Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
|
Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
|
|
アクティブコンパレータ:2
Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
|
Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
薬物乱用治療への継続
時間枠:12ヶ月
|
12ヶ月
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
自己報告された HIV 感染リスク行動
時間枠:12ヶ月
|
12ヶ月
|
|
Visit attendance with primary medical provider
時間枠:12 months
|
12 months
|
|
Urine drug screen positivity for opioids and other drugs
時間枠:12 months
|
12 months
|
|
Use of and adherence to highly active antiretroviral therapy (HAART)
時間枠:12 months
|
12 months
|
|
HIV RNA changes
時間枠:12 months
|
12 months
|
|
CD4 cell count changes
時間枠:12 months
|
12 months
|
|
Costs and resource utilization
時間枠:12 months
|
12 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Gregory M Lucas, MD, PhD、Johns Hopkins University
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。